A comprehensive pan-cancer analysis of the prognostic role and immunotherapy efficacy evaluation of Glyoxalase 1

Abstract Background: Glyoxalase 1 (GLO1), an enzyme responsible for breaking down methylglyoxal (MG), is increasingly recognized as a tumor-promoting factor due to its role in removing cytotoxic MG. This study aims to analyze the expression status and prognostic significance of GLO1 across various cancers and explore its potential role in cancer immunotherapy. Methods: We obtained GLO1 mRNA expression profiles from The Cancer Genome Atlas (TCGA) database. Kaplan-Meier analysis was used to evaluate the prognostic value of GLO1 in multiple cancers.